Technology & Software Global On demand · 24-48h

Global NGS Tumor Gene Analysis Software Market Strategic Research Report

Name: Global NGS Tumor Gene Analysis Software Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global NGS Tumor Gene Analysis Software Market Strategic Res…

$3,500 USD

Strategic Research Report

Global NGS Tumor Gene Analysis Software Market

$2.31B2025

18.2%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Non-Small Cell Lung Cancer, Human 6 Gene Mutations, Human 12 Gene Mutations, Other

By Application: Hospitals and Health Systems, Research Institute, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine, GTH.O, Golden Helix, Inc, Diatech Pharmacogenetics, ViennaLab Diagnostics GmbH, 3D Medicines

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 102 pages

Market size 2025

$2.31B

Billion USD

Forecast CAGR

18.2%

2025-2032

Forecast 2032

$7.4B

Projected

Regions

Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global NGS Tumor Gene Analysis Software market size is predicted to grow from US$ 2,313 million in 2025 to US$ 7,285 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.

NGS (Next-Generation Sequencing) tumor gene analysis software refers to computer programs and tools designed to analyze genomic data obtained from the sequencing of tumor samples using next-generation sequencing technologies. These software applications are specifically developed to process and interpret the vast amount of genetic information generated by NGS platforms, allowing researchers and clinicians to identify genetic variants, mutations, and other genomic alterations associated with tumors.

Global key NGS Tumor Gene Analysis Software players cover Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, etc.

This report presents a comprehensive overview of the global NGS Tumor Gene Analysis Software market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Non-Small Cell Lung Cancer
Human 6 Gene Mutations
Human 12 Gene Mutations
Other

Segment by Application

Hospitals and Health Systems
Research Institute
Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global NGS Tumor Gene Analysis Software market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Hospitals and Health Systems, Research Institute, Other evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global NGS Tumor Gene Analysis Software Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 18.2%

Regional growth momentum

Market share by segment

Key metrics

Base value

$2.31B

2025

Forecast

$7.4B

2032

CAGR

18.2%

2025–2032

Regions

global

Key companies

RocheIlluminaThermo Fisher ScientificBGI GroupNovogeneGeneseeqAmoyDxBurning Rock Medicine

Segments covered in this report

By Type

Non-Small Cell Lung CancerHuman 6 Gene MutationsHuman 12 Gene MutationsOther

By Application

Hospitals and Health SystemsResearch InstituteOther

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Non-Small Cell Lung Cancer
3.1.3 Human 6 Gene Mutations
3.1.4 Human 12 Gene Mutations
3.1.5 Other
3.1.6 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Hospitals and Health Systems
4.1.3 Research Institute
4.1.4 Other
4.1.5 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Roche
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Illumina
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Thermo Fisher Scientific
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 BGI Group
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Novogene
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 Geneseeq
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 AmoyDx
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Burning Rock Medicine
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 GTH.O
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Golden Helix, Inc
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Diatech Pharmacogenetics
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 ViennaLab Diagnostics GmbH
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 3D Medicines
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global NGS Tumor Gene Analysis Software market?

The global NGS Tumor Gene Analysis Software market is estimated at US$ 2.31 billion in 2025 (base year) and is projected to reach US$ 7.29 billion by 2032.

What is the forecast CAGR for the NGS Tumor Gene Analysis Software market?

The market is expected to grow at a CAGR of 18.2% from 2026 to 2032, expanding from US$ 2.31 billion in 2025 to US$ 7.29 billion in 2032, roughly 3.2 times its base-year value.

What is NGS Tumor Gene Analysis Software?

What are the main segments of the NGS Tumor Gene Analysis Software market by type?

By type, the market is segmented into Non-Small Cell Lung Cancer, Human 6 Gene Mutations, Human 12 Gene Mutations and Other.

Which applications drive demand in the NGS Tumor Gene Analysis Software market?

Key applications covered include Hospitals and Health Systems, Research Institute and Other.

Who are the key players in the NGS Tumor Gene Analysis Software market?

Key players profiled include Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, Geneseeq, AmoyDx and Burning Rock Medicine, among 13 companies covered in total.

Which regions and countries are covered for NGS Tumor Gene Analysis Software?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the NGS Tumor Gene Analysis Software market report?

The report is intended for manufacturers and solution providers, distributors and end users in Hospitals and Health Systems, Research Institute and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the NGS Tumor Gene Analysis Software market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.